The Real-World Clinical Benefits of GLP-1 Receptor Agonist Treatment
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
The cardiovascular, metabolic and renal benefits of glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been established in randomized trials with carefully selected patients. Real-world evidence of GLP-1RA effects on progression to end-stage renal disease (ESRD), end-stage liver disease (ESLD), and major adverse cardiovascular events (MACE) is scant.
Methods
We conducted a large retrospective cohort study of GLP1-RA use in adults using a national medical and pharmacy claims dataset. GLP-1RA users were stratified by diabetes status and propensity score-matched to controls. Outcomes were incident ESRD, ESLD, MACE overall and by treatment persistence (<1 year, 1–<2 years, ≥2 years). Cox models were used to estimate adjusted hazard ratios (HRs) and to calculate confidence intervals (CIs).
Results
In members with diabetes, GLP-1RA therapy was associated with reduced risks of ESRD (HR, 0.55; 95% CI, 0.49 to 0.61), ESLD (HR=0.66; 95% CI 0.60-0.73) and MACE (HR=0.90; 95% CI 0.86-0.93). In members without diabetes, while the incidence rates of adverse outcomes were lower, treatment with GLP-1RAs still resulted in lower risk of ESRD (HR=0.66, CI 0.46-0.94), ESLD (HR-0.76, CI 0.62-0.93) and MACE (HR=0.86, CI 92-0.99). Persistent GLP-1RA treatment (≥2 years) in members with diabetes resulted in the largest observed reduction in ESRD, ESLD, and MACE risk.
Conclusions
GLP-1RA treatment was associated with reduced incidence of kidney and liver failure and MACE. The impact of GLP-1RA treatment was greatest in members with diabetes and those persisting for ≥2 years.
